Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ACRV with free AI briefings, catalyst countdowns, and dilution alerts.

ACRV · Acrivon Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$90M Cash on Hand
15.2mo Cash Runway
20% Short Interest
$11.5 Analyst Target (6)
Follow ACRV by email Get an email when ACRV reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ACRV, unsubscribe in one click. Privacy

📣 What ACRV Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Wee1/PKMYT1 Inhibitor ACR-2316 Specific Advanced Solid Tumors Phase 1/2 · NCT06667141 Recruiting
Prexasertib (ACR-368) Head and Neck Squamous Cell Carcinoma Phase 2 · NCT06597565 Recruiting

Also used in these trials (approved or third-party drugs, not ACRV's own candidates): Gemcitabine Hydrochloride.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ACRV holds $90M in cash and short-term investments (as of Jun 30, 2026) and burns about $17.7M/quarter from operations, an estimated runway of 15.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 72 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ACRV files for a raise →

👥 Who Owns ACRV

Insiders 8.2% Other 5%+ holders 5.3% Institutions (59 holders) 49.9% Public and other holders 36.6%
HolderTypeShares% of sharesAs of
Peter Blume-Jensen
President and CEO, Director
Insider 2,615,911 6.10% 2026-08-25
Sands Capital Life Sciences Pulse Fund I 5%+ holder (13G) 2,289,271 5.33% 2026-06-30
Sands Capital Alternatives, LLC Institution (13F) 2,122,605 4.95% 2025-12-31
Kenneth Griffin Institution (13G, 5%+) 1,721,867 4.01% 2025-11-14
Citadel Advisors Llc Institution (13F) 1,641,884 3.83% 2025-12-31
Wellington Management Group, LLP Institution (13F) 888,130 2.07% 2025-12-31
Vanguard Group Inc Institution (13F) 698,857 1.63% 2025-12-31
Renaissance Technologies, LLC Institution (13F) 634,169 1.48% 2025-12-31
Two Sigma Investments, LP Institution (13F) 585,069 1.36% 2025-12-31
Acadian Asset Management. LLC Institution (13F) 581,208 1.35% 2025-12-31
Marshall Wace LLP Institution (13F) 496,081 1.16% 2025-12-31
RA CAPITAL MANAGEMENT, L.P.
Director, 10% owner · +20,275 options
Insider 426,302 0.99% 2026-05-18

Share count 42,911,680 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2025-12-31). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-08-31
filed 2026-09-02
Levin Michaela
Award (A) 30,000 – 30,000
2026-08-31
filed 2026-09-02
Levin Michaela
Option award (A) 130,000 – –
2026-08-25
filed 2026-08-27
Blume-Jensen Peter
Sale (S) 14,036 $2.21 2,230,052
2026-08-18
filed 2026-08-20
Peterson Katharine
Sale (S) 101 $2.01 18,033
2026-08-18
filed 2026-08-20
Miller Mary
Sale (S) 185 $2.01 82,009

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full ACRV picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ACRV and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.